Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
ILB-M5253 | Mouse | Mouse IL-2 R beta / CD122 Protein, Fc Tag | ![]() |
![]() ![]() |
|
ILA-C52H5 | Canine | Canine IL-2 R beta Protein, His Tag | ![]() |
![]() ![]() |
|
ILA-M52H5 | Mouse | Mouse IL-2 R beta Protein, His Tag | ![]() |
![]() ![]() |
|
ILB-H82E3 | Human | Biotinylated Human IL-2 R beta / CD122 Protein, His,Avitag™ | ![]() |
![]() ![]() |
![]() ![]() ![]() ![]() |
ILB-H5253 | Human | Human IL-2 R beta / CD122 Protein, Fc Tag (MALS & SPR verified) | ![]() |
![]() ![]() |
![]() ![]() ![]() ![]() |
CD2-H5221 | Human | Human IL-2 R beta / CD122 Protein, His Tag (SPR verified) | ![]() |
![]() ![]() |
![]() ![]() |
Human IL-2 R beta, Fc Tag (Cat. No. ILB-H5253) captured on CM5 chip via anti-human IgG Fc antibody can bind IL-2, Tag Free (Cat. No. IL2-H4113) with an affinity constant of 0.473 μM as determined in a SPR assay (Biacore T200) (QC tested).
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Denileukin diftitox | E-7272; E-7777; DAB-389; LY-335348; DAB389IL-2 | Approved | Eisai Co Ltd | Ontak, Onzar | United States | Lymphoma, T-Cell, Cutaneous | Eisai Inc | 1999-02-05 | Lymphoma, T-Cell, Peripheral; Lymphoma, B-Cell; Leukemia; Lymphoma, T-Cell, Cutaneous; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Melanoma | Details |
Basiliximab | CHT-25; chRFT5; CHI-621; SDZ-CHI-621 | Approved | Novartis Pharma Ag | 舒莱, Simulect | Japan | Rejection of organ transplantation | Novartis Pharma Ag | 1998-05-12 | Rejection of renal transplantation; Rejection of organ transplantation; Colitis, Ulcerative; Uveitis | Details |
Daclizumab | R-35; BIIB-019; RO-247375 | Approved | Abbvie Inc, Biogen Inc, F. Hoffmann-La Roche Ltd | Zinbryta, Zenapax | United States | Multiple Sclerosis | Biogen Inc | 1997-12-10 | Multiple Sclerosis, Relapsing-Remitting; Gastrointestinal Diseases; Inflammatory Bowel Diseases; Multiple Sclerosis; Rejection of organ transplantation; Asthma; Colitis, Ulcerative | Details |
Daclizumab biosimilar (Shanghai CP Guojian) | Approved | Shanghai Cp Guojian Pharmaceutical Co Ltd | 健尼哌 | Mainland China | Rejection of renal transplantation | null | 2011-01-12 | Rejection of renal transplantation | Details | |
Recombinant Human Interleukin-2(Ⅰ) (Liaoning Satellite Biological Products) | Approved | Liaoning Satellite Biological Products Research Institute (Limited) | Mainland China | Neoplasms | Liaoning Satellite Biological Products Research Institute (Limited) | 2002-02-04 | Neoplasms | Details | ||
Denileukin diftitox | E-7272; E-7777; DAB-389; LY-335348; DAB389IL-2 | Approved | Eisai Co Ltd | Ontak, Onzar | United States | Lymphoma, T-Cell, Cutaneous | Eisai Inc | 1999-02-05 | Lymphoma, T-Cell, Peripheral; Lymphoma, B-Cell; Leukemia; Lymphoma, T-Cell, Cutaneous; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Melanoma | Details |
Basiliximab | CHT-25; chRFT5; CHI-621; SDZ-CHI-621 | Approved | Novartis Pharma Ag | 舒莱, Simulect | Japan | Rejection of organ transplantation | Novartis Pharma Ag | 1998-05-12 | Rejection of renal transplantation; Rejection of organ transplantation; Colitis, Ulcerative; Uveitis | Details |
Daclizumab | R-35; BIIB-019; RO-247375 | Approved | Abbvie Inc, Biogen Inc, F. Hoffmann-La Roche Ltd | Zinbryta, Zenapax | United States | Multiple Sclerosis | Biogen Inc | 1997-12-10 | Multiple Sclerosis, Relapsing-Remitting; Gastrointestinal Diseases; Inflammatory Bowel Diseases; Multiple Sclerosis; Rejection of organ transplantation; Asthma; Colitis, Ulcerative | Details |
Daclizumab biosimilar (Shanghai CP Guojian) | Approved | Shanghai Cp Guojian Pharmaceutical Co Ltd | 健尼哌 | Mainland China | Rejection of renal transplantation | null | 2011-01-12 | Rejection of renal transplantation | Details | |
Recombinant Human Interleukin-2(Ⅰ) (Liaoning Satellite Biological Products) | Approved | Liaoning Satellite Biological Products Research Institute (Limited) | Mainland China | Neoplasms | Liaoning Satellite Biological Products Research Institute (Limited) | 2002-02-04 | Neoplasms | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Basiliximab biobetter (Mabtech/Sorrento) | STI-003 | Phase 3 Clinical | Taizhou Maibo Taike Biotechnology Co Ltd | Autoimmune Diseases | Details |
Anti-interleukin-2 receptor monoclonal antibody Mikbeta1 | HuMikβ1-1 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd, National Institutes Of Health | Leukemia, Lymphoid | Details |
RO-7296682 | RO-7296682; RG-6292 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Solid tumours | Details |
Inolimomab | B-B10; BT-563; MAb-BT-563 | Phase 3 Clinical | Eusa Pharma, Jazz Pharmaceuticals | Graft vs Host Disease | Details |
XmAb-564 | XmAb-564; XmAb-27564 | Phase 1 Clinical | Xencor | Autoimmune Diseases | Details |
Camidanlumab tesirine | ADCT-301 | Phase 2 Clinical | Genmab, Adc Therapeutics | Hodgkin Disease; Melanoma; Carcinoma, Non-Small-Cell Lung; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Fallopian Tube Neoplasms; Colorectal Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Urinary Bladder Neoplasms; Solid tumours; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms; Ovarian Neoplasms | Details |
MDNA-11 | MDNA-11; MDNA11 | Phase 2 Clinical | Medicenna Therapeutics Corp | Cholangiocarcinoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Melanoma; Uterine Neoplasms; Carcinoma, Squamous Cell; Gallbladder Neoplasms; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Sarcoma; Solid tumours; Urinary Bladder Neoplasms; Triple Negative Breast Neoplasms; Carcinoma, Merkel Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Basal Cell; Carcinoma, Renal Cell; Stomach Neoplasms; Ovarian Neoplasms; Biliary Tract Neoplasms | Details |
ANV-419 | Phase 2 Clinical | Anaveon AG | Solid tumours; Multiple Myeloma | Details | |
In 111-DOTA-Basiliximab | Phase 1 Clinical | City Of Hope National Medical Center | Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute | Details | |
90Y Basiliximab | Phase 2 Clinical | City Of Hope National Medical Center | Lymphoma, T-Cell, Peripheral; Hodgkin Disease; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin | Details | |
PT-101 | MK-6194; PT-101 | Phase 1 Clinical | Pandion Therapeutics | Autoimmune Diseases; Colitis, Ulcerative | Details |
RM-1995 | RM-1995 | Phase 1 Clinical | Rakuten Medical Inc | Squamous Cell Carcinoma of Head and Neck; Carcinoma, Squamous Cell | Details |
Basiliximab biobetter (Mabtech/Sorrento) | STI-003 | Phase 3 Clinical | Taizhou Maibo Taike Biotechnology Co Ltd | Autoimmune Diseases | Details |
Anti-interleukin-2 receptor monoclonal antibody Mikbeta1 | HuMikβ1-1 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd, National Institutes Of Health | Leukemia, Lymphoid | Details |
RO-7296682 | RO-7296682; RG-6292 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Solid tumours | Details |
Inolimomab | B-B10; BT-563; MAb-BT-563 | Phase 3 Clinical | Eusa Pharma, Jazz Pharmaceuticals | Graft vs Host Disease | Details |
XmAb-564 | XmAb-564; XmAb-27564 | Phase 1 Clinical | Xencor | Autoimmune Diseases | Details |
Camidanlumab tesirine | ADCT-301 | Phase 2 Clinical | Genmab, Adc Therapeutics | Hodgkin Disease; Melanoma; Carcinoma, Non-Small-Cell Lung; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Fallopian Tube Neoplasms; Colorectal Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Urinary Bladder Neoplasms; Solid tumours; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms; Ovarian Neoplasms | Details |
MDNA-11 | MDNA-11; MDNA11 | Phase 2 Clinical | Medicenna Therapeutics Corp | Cholangiocarcinoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Melanoma; Uterine Neoplasms; Carcinoma, Squamous Cell; Gallbladder Neoplasms; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Sarcoma; Solid tumours; Urinary Bladder Neoplasms; Triple Negative Breast Neoplasms; Carcinoma, Merkel Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Basal Cell; Carcinoma, Renal Cell; Stomach Neoplasms; Ovarian Neoplasms; Biliary Tract Neoplasms | Details |
ANV-419 | Phase 2 Clinical | Anaveon AG | Solid tumours; Multiple Myeloma | Details | |
In 111-DOTA-Basiliximab | Phase 1 Clinical | City Of Hope National Medical Center | Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute | Details | |
90Y Basiliximab | Phase 2 Clinical | City Of Hope National Medical Center | Lymphoma, T-Cell, Peripheral; Hodgkin Disease; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin | Details | |
PT-101 | MK-6194; PT-101 | Phase 1 Clinical | Pandion Therapeutics | Autoimmune Diseases; Colitis, Ulcerative | Details |
RM-1995 | RM-1995 | Phase 1 Clinical | Rakuten Medical Inc | Squamous Cell Carcinoma of Head and Neck; Carcinoma, Squamous Cell | Details |
This web search service is supported by Google Inc.